New foreign investment rules are yielding positive results for India's economy. Twenty-nine investment proposals totaling over Rs 4,895 cro...

India Private Equity Investment 2026: Geopolitical risks now shape private equity deal considerations in India. Investors increasingly focu...

Pharmaceuticals giant Cipla announced its merger with Inzpera Healthsciences Limited on Wednesday. This consolidation aims for more efficie...

Symbiotec Pharmalab will launch its ₹1,757-crore IPO from August 24–27, 2026, with a price band of ₹938–988 per share. The minimum bid is 1...

For the growth of India's pharmaceutical sector, prioritizing innovation and advanced manufacturing is essential. Experts indicate that inc...

Aurobindo Pharma announced its subsidiary Eugia Pharma received a USFDA warning letter. This follows an inspection of their Telangana formu...

The Bombay High Court has told the Tukaram Mundhe-led Maharashtra FDA to use its powers judiciously after Cadila Pharmaceuticals challenged...

The government has initiated 950 enforcement actions against pharmaceutical companies since December 2022. These actions aim to improve the...

Maharashtra FDA has launched a statewide crackdown on Ayurvedic drug manufacturers. Inspections revealed serious violations of manufacturin...

For Indian pharma, the regulatory risk is still real. A US FDA inspection can still cause trouble. A plant making an important product or g...

India has spent years negotiating free trade agreements with some of the world's biggest economies. But signing the deals was only half the...

Fire protection systems manufacturer HD Fire Protect is planning to launch its IPO in October through an offer for sale of 2.6 crore shares...

The EU offers the biggest long-term opportunity for Indian medical device makers, while the UK has more immediate strategic value, says AiM...

India's food regulator has suspended Switz Foods' manufacturing licence. Serious non-compliances were found during a recent unit inspection...

Maharashtra FDA plans to approach the NPPA regarding exorbitant drug prices. The agency is examining data and will take action against unet...

Amid increasing global concerns over Indian pharmaceuticals, India's drug regulator is rigorously addressing high-risk manufacturing sites....

The FSSAI has suspended Dior Pharmaceuticals' license due to serious violations. The nutraceutical factory operated with severely deficient...